Study type: Review2008
Cannabinoid pillar · varin series
Tetrahydrocannabivarin (THCV).
Does THCV help with appetite or weight loss?
No published human result shows that it does. evidence state: No primary evidence
THCV sells harder than its evidence. It sells as diet weed, the cannabinoid that is supposed to curb appetite and help with weight, and it borrows a family likeness it only half has. Chemically it is the propyl homolog of THC, grown on its own branch of the plant, a different thing from the shortened THC of the usual shorthand. The appetite story comes apart faster. Not one published study reports an appetite result in THCV's favour, and the metabolic trial in patients missed its own primary endpoint. Then there is the 207-patient Phase 2 built to settle the question. It finished in 2016 and was never published, and ten years on its result is still known only to the sponsor.
Sources verified·21 studies·updated 9 August 2026·How we check
On this page18 sections
Origin & biosynthetic role
THCV is not shortened THC.
The family tree is where the confusion starts. The version you hear most often has the plant making THC and then trimming two carbons off it. The plant runs a parallel line instead, from a different acid. The same enzyme family that makes THC's acid takes the varin precursor CBGVA and turns it into THCVA, and heat then strips the CO₂ to leave neutral THCV. Step for step, the route mirrors the pentyl one that begins at CBGA. THC appears nowhere along it.
CBGVA
varin precursor (C₃)
THCA synthase
enzyme
THCVA
varin branch acid
Δ9-THCV
heat removes CO₂
The varin line, which ends in THCV. Its enzymology is inferred from the characterised pentyl reaction below, the one our registry covers.
CBGA
pentyl precursor (C₅)
THCA synthase
enzyme
THCA
branch acid
Δ9-THC
heat removes CO₂
The pentyl line: the verified biosynthesis the varin line runs beside. Δ9-THC and Δ9-THCV are siblings, each made from its own acid, and no arrow joins them.
Why the family tree matters for product copy
“THC with a shorter tail” invites the buyer to hear “milder THC”, and the pharmacology can point the other way. At the CB1 receptor, THCV blocks the cannabinoids that THC activates, until the dose rises and the direction flips. A molecule that can oppose THC at one amount and imitate it at another is its own drug with its own rules. Copy that sells it as a lighter THC is describing a molecule that exists only in the copy. The receptor detail sits in the mechanism section, at Researcher depth.
Ask the supplier: six questions about THCV.
Six questions to put to a supplier, each followed by the position the registry or this compound's page already holds, in its own words. The questions ask what the supplier states; none asks what anyone should take. Informational only, not medical or legal advice.
- 1Which isomer is in the jar, Δ9-THCV or Δ8-THCV?
- Two molecules share the abbreviation and their published pharmacology is separate: “A jar labelled plain “THCV” leaves you guessing which is inside.”Not graded in our registryOn the THCV page →
- 2How many milligrams of THCV per serving?
- Size the label against the record: “The longest published human exposure is thirteen weeks, in 62 people, at 5 mg twice daily”, and single acute doses ran higher. A trial dose is a scale, not guidance.Not graded in our registryJadoon 2016 · On the THCV page →
- 3Does the label say non-psychoactive, and at what dose?
- The pillar refuses the blanket form: “Non-psychoactive” without qualification goes past the evidence. Ask which dose the statement is meant for.Not graded in our registryPeters 2023 · On the THCV page →
- 4Does the label claim appetite control?
- On the appetite claim the pillar is plain: “No human result supports it, and the record is unusually clear.”Not graded in our registryOn the THCV page →
- 5What does the supplier say about drug testing?
- In a registered human study “78 of 79 urine screens taken 8 hours after oral THCV were positive for THC”. Ask whether the label warns anyone who is tested.Not graded in our registryPeters 2023; Sempio 2026 · On the THCV page →
- 6Is the THCV a purified compound at a stated milligram figure, or a “high-THCV” plant material?
- After a controlled dose of edible cannabis THCV was never detected in blood at the study's cut-offs: “A “high-THCV strain” is not a way to get a THCV dose.”Not graded in our registryNewmeyer 2017 · On the THCV page →
Take the answers to the paperwork: Read a COA, then test the label wording. How the site grades what it holds is on How we grade.
The knowledge boundary
Where the THCV evidence stops.
Strip the marketing away and a fair amount about THCV is settled: what it is, where it comes from, that its receptor directions are published with a dose condition, and that people have taken it in controlled trials. The claims that sell it sit on the far side of the line, and they sit there for three quite different reasons.
Established
- ✓Chemical identityC₁₉H₂₆O₂ (≈ 286.4 g/mol). The same tetrahydrocannabinol skeleton as THC, with a side chain two carbons shorter: propyl (C₃) where THC carries pentyl (C₅).
- ✓It comes from its own acid, not from THCThe plant builds THCV on a parallel line of its own. THCA synthase converts the varin precursor CBGVA to THCVA, and heat strips the CO₂ to leave neutral Δ9-THCV, mirroring CBGA → THCA → Δ9-THC step for step. Our registry documents the characterised pentyl reaction; the varin branch is inferred from it.
- ✓Its receptor directions are published, with a dose conditionA 2008 review states them in its abstract, and we quote them word for word: in CB1-expressing tissues THCV blocks cannabinoid agonists, and in live animals it acts as a CB1 antagonist or, at higher doses, as a CB1 agonist. Strip out the dose and you have changed the finding.
- ✓It has been given to people, in registered controlled trialsOnly a handful of small trials, all covered here: a 62-participant metabolic pilot, an interaction study in ten men, and a dose-ranging safety and pharmacokinetics programme that went up to 200 mg. What they found sits in the next column.
- ✓At higher doses it produces effects people can feelTHCV is often sold as non-psychoactive. In the dose-ranging safety study, though, 100 mg and 200 mg raised ratings of “feel a drug effect” and “like the drug effect”, and the authors report THC-like effects at higher THCV doses. At the top of the tested range, people noticed, and the label does not hold.
- ✓It can make a urine drug screen read positive for THCIn the same programme, nearly every post-dose urine screen came back positive for THC. When a follow-up analysis ran the pooled samples through a routine immunoassay, most were flagged, and the reference method found no Δ9-THC-COOH in them at all. Documented false positives, in people, from a product that isn't THC.
Not yet established
- —Any approved use for diabetes, weight loss or appetiteNot established. No THCV medicine is approved for any indication in any jurisdiction, and nothing here suggests that THCV treats, prevents or manages type 2 diabetes, obesity or any other condition.
- —The metabolic trial's own primary endpointTested, and it failed. The 62-participant trial registered HDL cholesterol as its primary endpoint, the outcome it chose in advance, and the paper reports “plasma HDL was unaffected”. A result, then, and a negative one.
- —Appetite suppression, in a personNot established, and it is the claim THCV is sold on. The metabolic trial registered appetite as a secondary endpoint and scored it daily for thirteen weeks; the published paper is silent on it. Two studies that asked people to rate their responses directly found no significant difference from placebo. No positive human appetite result exists to cite.
- —Which direction THCV takes at CB2Unresolved. One paper reports a CB2 partial agonist; another, from the same laboratory lineage, reports a CB2 antagonist. Both remain in print and unretracted, so both stay in the record.
- —Where the CB1 dose flip sits in a personNot established. The switch from antagonist to agonist has been documented in mice given THCV intravenously, and there the trail ends. Nobody has found the equivalent point for a person taking THCV by mouth, which is why we call no human dose “low” or “high”.
- —Long-term safety, and drug interactionsNot established. The longest published exposure is thirteen weeks in 62 people, and the dose-ranging safety study used single acute doses. No drug-interaction study in people has been published, and a year on THCV is longer than anyone has been followed.
Three kinds of gap, and why the difference matters
Tested, and the endpoint came back null. The metabolic trial's HDL primary and the subjective ratings in both imaging studies are results, and they count. Never tested. Long-term safety, and where the CB1 dose flip sits in a person: nobody has run those studies. Tested, finished, and never published. A 207-patient Phase 2 completed a decade ago, and its result stays with the sponsor. The third kind is the rarest and the heaviest, and it gets a section of its own further down rather than being filed under “more research is needed”. A missing study, a negative result and a withheld one each tell you something different. Our evidence ladder keeps Not-supported for evidence that weighs against a claim, and that grade is set in our evidence registry.
The registry · THCV
1 of the 21 studies in our registry concern THCV
- a study linked to THCV
- the rest of the registry
- human trial
Study design, not evidence grade. The rows say how a study was run; they say nothing about the standing of any claim. A tier describes a study; a grade describes a claim.
What has been tested in people
The human record.
Which brings us to people. Two published trials have given THCV to people to test what it does: a metabolic trial in patients, and an interaction study against THC. Read what was actually tested before reading what it found, and keep the shows / does not show pair together, because the distance between a study's design and a product's claim is where claims go wrong. The safety and pharmacokinetic programme gets its own section later; it measured how well people tolerate THCV rather than whether it helps them.
Cited, but not graded
These papers are published and anyone can check them, but they have yet to enter the CBG Atlas registry as graded entries, so they carry no rung on our evidence ladder. The badge beside each names the study's design. Once a paper joins the registry, it takes a grade like any other record.
2016
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
What was actually tested: 62 people with non-insulin-treated type 2 diabetes, randomised double-blind into five parallel arms for 13 weeks: CBD 100 mg twice daily; THCV 5 mg twice daily; a 1:1 CBD:THCV combination (5 mg/5 mg twice daily); a 20:1 combination (100 mg/5 mg twice daily); or matched placebo. Twelve or thirteen people per arm, in other words, in a study its own title calls a pilot (PubMed files it under the MeSH term “Pilot Projects”). The registration (NCT01217112) lists the condition as dyslipidaemia in type 2 diabetes and required low HDL at screening, so the design was built around a lipid question, and its brief summary names GW Pharma Ltd as the company that ran it. The study ran from October 2010 to September 2012. The paper came out in 2016, four years after the last participant finished.
The trial was registered to move HDL cholesterol, and the paper reports that “plasma HDL was unaffected”: a missed primary endpoint. What THCV on its own did move was fasting plasma glucose, lower than on placebo (estimated treatment difference −1.2 mmol/L, P < 0.05). It also shifted pancreatic β-cell function (HOMA2), adiponectin and apolipoprotein A by statistically significant amounts, and the direction of those three is unclear. The abstract calls all three “improved”, yet every treatment difference it prints for them is negative, and the registration counts an increase as the improvement for β-cell function and apolipoprotein A. They moved; which way is an open question. Then comes the sentence summaries tend to skip: “None of the combination treatments had a significant impact on end points.” The CBD results, as the paper itself notes, are measured against baseline rather than placebo.
What it shows: In a 62-person pilot in type 2 diabetes, THCV 5 mg twice daily for thirteen weeks lowered fasting plasma glucose relative to placebo and moved three other blood measures by a statistically significant amount.
What it does NOT show: That THCV treats diabetes or raises HDL: HDL, the endpoint chosen in advance, stayed where it was. On appetite the paper is silent, though appetite was registered as a secondary endpoint and scored daily for all thirteen weeks. CBD-plus-THCV products get nothing from it either, because every combination arm was null. And a blood-marker shift over thirteen weeks in about a dozen people per arm falls short of a clinical outcome; better-controlled diabetes was never shown.
Caveat: Industry-run, and its conclusion reaches past its data. Colin Stott is listed with a GW Pharmaceuticals affiliation, and the registration names GW Pharma Ltd as the company that ran the study. The abstract closes by saying THCV “could represent a new therapeutic agent in glycemic control”, a line built on secondary endpoints in a pilot whose primary came back null, and one we leave with its authors. The sequel matters more. The same sponsor went on to run a 207-patient Phase 2 with HbA1c as the primary endpoint, and that trial has never been published.
Randomised, placebo-controlled · in people · pilot · primary endpoint missedNot graded in our registry
2016
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
What was actually tested: Ten male cannabis users, each with fewer than 25 lifetime occasions of use, in a within-subject, placebo-controlled, double-blind crossover pilot. Each took 10 mg of pure oral THCV or placebo daily for five days, then received 1 mg of intravenous Δ9-THC on day five. The question was narrow: does THCV blunt THC? THCV's effects on their own, and anything metabolic, sat outside it.
On its own, THCV was well tolerated and felt like placebo. Alongside THC it did two things. It damped the heart-rate rise THC caused (p = 0.028), and nine of the ten men rated the THC as weaker or less intense after THCV (p = 0.011). But one outcome got worse: “THCV in combination with THC significantly increased memory intrusions” (p = 0.031). The abstract also marks the limit of the experiment: “THC did not significantly increase psychotic symptoms, paranoia or impair short-term memory, while still producing significant intoxicating effects.” The authors ask for cautious interpretation, citing the small sample and the absence of THC-induced psychotomimetic and memory-impairing effects, “probably owing to the choice of dose”.
What it shows: Five days of 10 mg THCV blunted the heart-rate rise from a small intravenous dose of THC in ten men, and most of them found the THC weaker.
What it does NOT show: That THCV protects against THC's psychological effects. The THC dose barely produced any, as the authors acknowledge: psychotic symptoms, paranoia and short-term memory showed no significant change, which left little to protect against. Calling THCV harmless alongside THC is a stretch too, with memory intrusions up. Metabolism, appetite and weight lay outside the study, an interaction pilot in ten men.
Caveat: This is the study usually cited for “THCV counteracts THC”, and anyone citing it owes the reader the rest of the abstract, which reports a worse outcome too. The heart-rate result travels well; the memory-intrusion result belongs beside it. Ten participants, all male, one dose level, one THC challenge.
Crossover pilot · in people · n = 10 · an interaction study, not an efficacy trialNot graded in our registry
Primary · secondary · tertiary
Which THCV endpoint moved — and which one the trial existed to test?
Here the story turns on a piece of trial plumbing that sales copy tends to skip. Before a trial starts, it names one outcome as the one that will answer its question, and everything else is secondary. A good secondary result does not make up for a missed primary; the primary is still the answer. So each trial leads with the result that matters, and every outcome it registered, in the order ClinicalTrials.gov ranks them, sits a click underneath.
Jadoon 2016 — THCV 5 mg twice daily, 13 weeks, n = 62 across five arms
NoteThe line that gets quoted, and what the trial actually found
The version that circulates: “a clinical trial showed THCV lowers blood sugar in type 2 diabetes”. Look closer. Fasting glucose was a secondary endpoint, measured in about a dozen people on THCV, in a study its own title calls a pilot. The question the trial set itself, HDL in people enrolled for low HDL, came back unaffected. And the appetite endpoint, the one closest to why people buy THCV, was registered, scored daily for thirteen weeks and never reported.
Every outcome this trial registered, in rank order
Registration: NCT01217112 (study code GWMD1092). Registered conditions: dyslipidaemia and type 2 diabetes. Participants needed low HDL at screening (≤ 1.3 mmol/L for women, ≤ 1.2 mmol/L for men), so they were chosen for the lipid problem the primary endpoint measured. The registration's summary says GW Pharma Ltd ran the study; GWP42004 is THCV and GWP42003 is CBD. Results are posted to the registration. Funding: Industry. Colin Stott is listed with a GW Pharmaceuticals affiliation on the paper. The registration names GW Pharma Ltd as the company that ran it and Jazz Pharmaceuticals as sponsor of record.
| Registered rank | Pre-specified outcome | What happened |
|---|---|---|
| PrimaryNot met | Change from baseline in mean serum HDL cholesterol concentration after 91 days (13 weeks) of treatment — the registration adds that an increase indicates improvement | Missed. People were enrolled because their HDL was low, the trial was designed around raising it, and the paper's verdict is “although plasma HDL was unaffected”. |
| SecondarySignificant | Change from baseline in mean fasting glucose concentration | Lower on THCV alone than on placebo: estimated treatment difference −1.2 mmol/L, P < 0.05. Here the wording and the sign agree, so the direction is clear. |
| SecondarySignificant · direction unresolved | Change from baseline in mean insulin β-cell function measured by HOMA2 — the registration adds that an increase indicates improvement | Significant, direction unresolved. The paper calls β-cell function “improved” but prints ETD = −44.51 points, P < 0.01. A negative value is a decrease, and the registration counts an increase as improvement. Until the full text resolves the mismatch, we report the significance and leave the direction open. |
| SecondarySignificant · direction unresolved | Change from baseline in mean serum apolipoprotein A concentration — the registration adds that an increase indicates improvement | Significant, direction unresolved. Called “improved”, printed as ETD = −6.02 μmol/L, P < 0.05. The same mismatch as the row above. |
| SecondarySignificant · direction unresolved | Adiponectin (reported in the paper among the endpoints THCV moved) | Significant, direction unresolved. Called “improved”, printed as ETD = −5.9 × 10⁶ pg/mL, P < 0.01. |
| SecondaryNot reported | Change from baseline in mean appetite, scored daily by participants on a 0–10 numerical rating scale for the whole 13 weeks | Registered, and scored every day for thirteen weeks. THCV's consumer reputation rests on this endpoint, and the published paper is silent on it. |
| SecondaryNot reported | Change from baseline in mean glycated haemoglobin (HbA1c) concentration | A registered secondary, missing from the published abstract. HbA1c then became the primary endpoint of the 207-patient trial below, the one that has stayed unpublished. |
| SecondaryNot reported | Change from baseline in mean body weight, BMI, waist measurement, waist-to-hip ratio, and total, visceral, subcutaneous and liver fat by magnetic resonance imaging | All registered as secondary outcomes, and all measured. The published abstract leaves every one of them out, so on THCV and body weight or body fat in people, we have nothing to report. |
| SecondaryNull | All endpoints, in the two CBD + THCV combination arms | Null. The paper: “None of the combination treatments had a significant impact on end points.” Any product combining the two is sold in spite of that sentence. |
| Tertiary / otherNot reported | Total and LDL cholesterol, HDL:LDL ratio, VLDL, triglycerides, apolipoprotein B, non-esterified fatty acids, fructosamine, OGTT glucose and insulin, fasting insulin, C-peptide, HOMA2-IR, insulin sensitivity, adverse events, and depression score (BDI-II) | Registered as secondary outcomes, and absent individually from the published abstract. Results are posted to the registration, and we go no further than a cited source goes. |
GWP42004 Phase 2 — 2, 5 and 15 mg twice daily added to metformin, 12 weeks, n = 207
NoteThe line that gets quoted, and what the trial actually found
Marketing has nothing to lift here, because nothing was released, and that is the problem. Every confident metabolic claim for THCV traces back to the 62-patient pilot above. The trial built to test that pilot's hypothesis properly, more than three times the size, with HbA1c as primary and twelve weeks on top of metformin, finished ten years ago and was never published. A summary that cites the pilot and skips the unpublished Phase 2 gives readers the favourable half of the story.
Every outcome this trial registered, in rank order
Registration: NCT02053272. A randomised, double-blind, placebo-controlled, parallel-group, dose-ranging Phase 2 of GWP42004 (THCV) added to metformin in type 2 diabetes, run at 25 sites in Romania and the United Kingdom. Started February 2014. Status: completed, primary completion February 2016. Ten years on, the registration shows no results and PubMed shows no paper: a search for the compound code “GWP42004” returns zero records (checked 2026-08-23). Funding: Industry. Sponsor of record: Jazz Pharmaceuticals. GWP42004 is a GW Pharmaceuticals compound code, the same one used in the registration of the 62-patient pilot above.
| Registered rank | Pre-specified outcome | What happened |
|---|---|---|
| PrimaryNever published | Change from baseline to end of treatment in mean glycosylated haemoglobin (HbA1c) — the single measure that would establish whether THCV improves glycaemic control | Unknown to everyone outside the sponsor. The trial completed in February 2016, and ten years on it has neither posted results nor produced a paper. The work was done. The result stayed private. |
| SecondaryNever published | Fasting plasma glucose; two-hour glucose and insulin on oral glucose tolerance testing; serum fructosamine; the number of participants reaching HbA1c below 7%; fasting insulin; HOMA2-IR; HOMA2-%B; pro-insulin; C-peptide | All registered, none published. The first is the one to watch: fasting plasma glucose is what the 62-person pilot moved, and the properly powered test of it is sitting in this unpublished trial. |
| SecondaryNever published | BMI; total cholesterol; HDL cholesterol; triglycerides; C-reactive protein; blood pressure | All registered, none published. HDL, the pilot's failed primary, appears here as a secondary. |
| SecondaryNever published | Incidence of adverse events; incidence of hypoglycaemic episodes; Beck Depression Inventory-II; Columbia-Suicide Severity Rating Scale; Cannabis Withdrawal Scale | Safety outcomes, registered and unpublished. 207 people took a cannabinoid twice daily for twelve weeks, and whatever the trial learned about their safety remains private. The depression and suicidality scales are there for a reason: the neighbouring drug class, CB1 blockers, was withdrawn for psychiatric harm. |
| Tertiary / otherNever published | Diabetes Treatment Satisfaction Questionnaire; overall health visual analogue scale | Registered. Never published. |
NoteHow a missed primary gets lost
Put the results in a paragraph and the ranking disappears. “THCV lowered blood sugar” and “the pre-specified endpoint was HDL, and it stayed flat” compete for the same sentence, and the shorter, happier one wins every time. Make the rank a column and a result travels with the rank it was registered under. The same discipline shows up what went missing: an endpoint that was registered and never reported still takes its place in the ranking, which is how the absent appetite result, and the whole of the second trial, come into view.
The unpublished Phase 2
207 patients. Twelve weeks. Finished in 2016. Never published.
The biggest fact in THCV's metabolic story is about paperwork rather than pharmacology. Every confident statement about THCV and blood sugar traces back to a 62-patient pilot whose own primary endpoint was null. The programme behind it then ran the trial that should have settled the question and carried it to the finish line, and its result has never been reported.
- Registration
- NCT02053272
- Registered title
- A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
- Sponsor
- Jazz Pharmaceuticals (sponsor of record). GWP42004 is a GW Pharmaceuticals compound code for THCV; the 62-patient pilot's registration uses the same code.
- Design
- Phase 2: randomised, double-blind, placebo-controlled, parallel-group, dose-ranging
- Participants
- 207 people with type 2 diabetes on a stable metformin dose, at 25 sites in Romania and the United Kingdom. They took 2, 5 or 15 mg twice daily, or placebo, for 12 weeks.
- Status
- Completed. Started February 2014; primary completion February 2016; overall completion February 2016.
- Primary endpoint
- Change from baseline to end of treatment in mean glycosylated haemoglobin (HbA1c). HbA1c tracks blood-glucose control over months, and it is the endpoint a diabetes medicine has to move.
- Results posted
- None. Ten years after completion, the results section is still empty.
- Publication
- None. No paper on this trial has appeared; a PubMed search for the compound code “GWP42004” returns zero records (checked 2026-08-23).
Why it outweighs any positive result
This was the trial meant to settle the question: more than three times the size of a 62-patient pilot that missed its own primary endpoint, with HbA1c as its primary endpoint, run on top of standard first-line therapy. HbA1c is the measure diabetes treatment is judged on. Every confident metabolic claim for THCV traces back to the pilot, and the trial built to test it finished with its result still private. For THCV and metabolism, that silence is the main story.
What it does not mean
That the trial failed. What it found is known only to the sponsor, and guessing would be inventing. Trials go unpublished for many reasons, among them commercial decisions, discontinued programmes and corporate restructuring, and reading a negative result into silence would be a claim without evidence. The narrower point is the one that stands: the largest test of THCV's best-known claim is missing from the record, and any summary of THCV's metabolic evidence that skips it passes off part of the record as the whole.
NoteThe same programme published its small trial four years late, and its large one not at all
The 62-patient pilot ran from October 2010 to September 2012 and reached print in 2016, four years after its last participant. The 207-patient Phase 2 started in February 2014 and completed in February 2016; a decade on, its registration still shows no results. Neither date tells you what THCV does in the body. Side by side, they tell you what kind of literature you are reading: a selected slice of the THCV evidence that exists. Any summary that skips this, the consumer explainers included, is describing the selection and calling it the science.
The claim THCV is sold on
“Diet weed” has no human evidence behind it.
Now to the claim that moves the product. Search the published record for a positive human result of any kind on appetite, food intake or body weight, and you come back empty-handed. A brand putting an appetite or weight claim on a THCV label has nothing from people to point to. Four sources bear on the question, and they are worth taking one at a time.
Four sources, four angles
One. Appetite was a registered secondary endpoint of the trial in patients. Participants scored it daily on a 0–10 scale for all thirteen weeks (NCT01217112), and when the paper appeared it carried no appetite result. Two. A brain-imaging study asked how much twenty volunteers wanted and liked food after a THCV dose. The answer was no significant differences in subjective ratings, even as brain responses to both reward and aversion went up (Tudge 2015). Three. A second study, again in twenty volunteers, reported no significant differences in the subjective experience (Rzepa 2016). Four. The mouse study the claim is traced to says, in its own words, that THCV “did not significantly affect food intake or body weight gain in any of the studies” (Wargent 2013). Four sources come at the question from four directions, and not one reports a positive appetite result.
2015
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers
What was actually tested: 20 healthy volunteers in a within-subject, double-blind design, each given a single 10 mg dose of THCV and placebo on two separate occasions in randomised order. Functional MRI recorded brain responses to rewarding stimuli (the sight and flavour of chocolate) and aversive ones (a picture of mouldy strawberries, a less pleasant strawberry taste). Volunteers rated each stimulus for pleasantness, intensity and wanting. A brain-imaging study, then, and food intake went unmeasured.
The volunteers' own ratings stayed flat: “There were no significant differences between groups in subjective ratings.” The scanner saw something else, and in both directions. THCV raised responses to chocolate in the midbrain, anterior cingulate cortex, caudate and putamen, and raised responses to the aversive stimuli in the amygdala, insula, mid-orbitofrontal cortex, caudate and putamen. The authors describe it as increased neural responding to both rewarding and aversive stimuli.
What it shows: A single 10 mg dose of THCV changed how twenty people's brains responded to food images and tastes, increasing the response to pleasant and unpleasant stimuli alike.
What it does NOT show: That THCV suppresses appetite. The measures closest to appetite, how much people wanted the food and how pleasant they found it, matched placebo. A stronger brain response to food reward, if it points anywhere, points toward more appetite, which is why the study gets quoted for its conclusion rather than its data. Nobody ate a meal, and nobody stepped on a scale.
Caveat: The line that travels is the conclusion, which suggests “therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects”. Read it for what it is: a hypothesis about a drug class, built on a brain-imaging pattern in twenty people whose own ratings stayed flat. Treat it as an appetite finding and the study's own data argue back.
Randomised crossover · in people · n = 20 · brain imaging, not eatingNot graded in our registry
2016
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
What was actually tested: 20 healthy volunteers, randomised in a within-subject, double-blind design to a single 10 mg oral dose of THCV and to placebo. Resting-state functional MRI, with seed-based connectivity analysis from the amygdala, insula, orbitofrontal cortex and dorsomedial prefrontal cortex. Self-report scales captured mood and subjective experience before and after dosing.
As the authors predicted, people felt the same as on placebo: “Our results revealed, as expected, no significant differences in the subjective experience with a single dose of THCv.” The connectivity maps did move. Links fell between the amygdala and the default mode network, and rose between the amygdala and the dorsal anterior cingulate cortex and between the dorsomedial prefrontal seed and the inferior and medial frontal gyri.
What it shows: A single 10 mg dose of THCV measurably changed resting brain connectivity in twenty healthy volunteers.
What it does NOT show: Anything about appetite, eating or weight, which went unmeasured. What it adds is a second independent sample in which 10 mg of THCV caused no detectable change in how a person feels. A connectivity pattern is a mechanistic observation, and the paper's suggestion of “possible therapeutic activity for obesity” is a hypothesis drawn from it, with clinical outcomes left untested.
Randomised crossover · in people · n = 20 · resting-state imagingNot graded in our registry
2013
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity
What was actually tested: Four oral dose-ranging studies, 30 to 45 days long, in two mouse models of obesity: diet-induced, and genetically obese (ob/ob). Cell work in insulin-resistant hepatocytes and myotubes ran alongside. A CB1 inverse agonist served as the positive control. The team measured food and water intake, body weight gain, energy expenditure, glucose and insulin, lipids and liver triglycerides. All in mice.
Follow the “diet weed” claim back far enough and it usually lands here, on a paper that says the opposite: “THCV did not significantly affect food intake or body weight gain in any of the studies, but produced an early and transient increase in energy expenditure.” What THCV changed was metabolism. It dose-dependently reduced glucose intolerance in ob/ob mice, improved glucose tolerance and insulin sensitivity in diet-induced obese mice, and restored insulin signalling in insulin-resistant cells. Plasma lipids did not change consistently.
What it shows: In two mouse models of obesity, oral THCV improved glucose handling and insulin sensitivity over 30 to 45 days.
What it does NOT show: That THCV reduces food intake or body weight. Across all four mouse studies it did neither, as the authors say directly, and the extra energy expenditure they saw was early and short-lived. It shows nothing about people. They come later, in the human pilot this preclinical work laid the groundwork for, and that pilot missed its primary endpoint.
Caveat: Same programme as the human pilot: co-author C. G. Stott is the author with a GW Pharmaceuticals affiliation on the 2016 trial. The animal work behind that trial is also the animal work most often cited, usually for a weight-loss result it does not contain.
Preclinical · mice · four dose-ranging studies · not peopleNot graded in our registry
2017
Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration
What was actually tested: Participants ate cannabis brownies in a controlled oral-dosing study, and their blood and oral fluid were sampled to map cannabinoid pharmacokinetics and to test roadside oral-fluid screening devices. Registered as NCT02177513. A forensic-toxicology study, in which THCV was one of several minor cannabinoids measured.
Tucked among the results is a line with real consumer weight: after people ate cannabis, THCV was “never detected in blood” at the study's analytical cut-offs, and it had cleared from oral fluid within hours. Eating cannabis that contains THCV did not reliably put measurable THCV into the bloodstream.
What it shows: The THCV naturally present in cannabis was undetectable in blood after people ate a controlled dose of that cannabis.
What it does NOT show: Anything about purified THCV sold as a product; the later dose-ranging pharmacokinetic study gave purified THCV by mouth and measured it in plasma without difficulty. Where it bites is the idea that certain cannabis varieties deliver a meaningful THCV dose. At the amounts in the material eaten here, none reached the blood.
Controlled human dosing · analytical chemistry · not a THCV trialNot graded in our registry
How the claim spreads anyway: the review behind it
So how does the appetite story keep spreading? Partly through a review that asserts appetite suppression. Set it beside the primary studies it summarises and the distance between what it says and what they found is plain to see. CBG Atlas cites it as evidence for nothing.
2025
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management
What was actually tested: A single-author narrative review of THCV in obesity and type 2 diabetes. It summarises other researchers' experiments; every data point in it is second-hand.
The review says THCV's receptor profile enables “appetite suppression, enhanced glucose regulation, and increased energy expenditure”, that animal models showed its potential to suppress appetite, and that “preliminary human trials support these findings”. Set those sentences beside the primary studies and they come apart. The mouse study found no significant effect on food intake or body weight gain in any of its experiments. Both human imaging studies found no significant difference in subjective experience. And the human metabolic trial registered appetite as a secondary endpoint, scored it daily for thirteen weeks and published no appetite result.
What it shows: How the appetite-suppression claim spreads: a secondary source states it in summary, with no primary human result behind it.
What it does NOT show: Any evidence for appetite suppression. A review is only as strong as the papers it cites, and on this point those papers are null, silent or contrary. We cite it as a specimen of the claim, never as support, and copy that leans on it inherits the same gap.
Caveat: Listed so the claim can be traced to its source, not as support, and so a reader can lay the review's summary beside the primary studies and compare.
Narrative review · single author · secondary source · asserts more than the primaries showNot graded in our registry
Safety, pharmacokinetics & drug testing
The finding a THCV buyer is most likely to need.
For anyone subject to workplace, sporting or custody testing, the finding that matters most on this page concerns drug tests. In a registered study, a legal THCV product made urine drug screens read positive for THC in nearly every participant. A follow-up analysis checked those results against a reference method and found the positives were false, which is cold comfort to anyone facing a workplace, sporting or custody screen with THCV in their system.
2023
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants
What was actually tested: Oral Δ8-THCV in healthy adults, in two phases, registered as NCT05210634. Phase 1 was an unblinded single-ascending-dose stage in 3 people. Phase 2 was a double-blind, randomised, within-participant crossover in 18. Each dose was a single acute one: placebo, 12.5, 25, 50, 100 and 200 mg. Safety, subjective and cognitive effects were measured before dosing and for up to 8 hours after. Mind the isomer: this programme used Δ8-THCV, while the metabolic literature is about Δ9-THCV.
Most adverse events were mild (55 of 60), and the commonest was euphoric mood. The top doses were noticeable. At 100 mg and 200 mg, ratings of “feel a drug effect” and “like the drug effect” rose, and the authors write that “THC-like effects were observed at higher THCV doses”, though mild and not linked to impairment. Several doses gave a preliminary signal for better sustained attention, in a pattern that should give anyone pause: 12.5, 25 and 200 mg moved it, 50 and 100 mg did not. A genuine dose-response would climb with the dose. For consumers, the result that matters most came from the urine. At 8 hours, 78 of 79 post-dose urine screens tested positive for THC.
What it shows: Healthy adults tolerated single oral doses of Δ8-THCV up to 200 mg, with mostly mild adverse events, and at the top of that range they could tell they had taken something.
What it does NOT show: That THCV is non-psychoactive; the authors themselves report THC-like effects at higher doses. Every dose was single and acute, so repeated dosing is unexplored, and every participant was healthy, so people with a medical condition went unstudied. A safety and dose-ranging study, it leaves therapeutic claims untested.
Caveat: Industry-authored: seven of the eight authors are affiliated with Canopy Growth Corporation. For consumers the drug-screen result outweighs the safety verdict. A legal product that isn't THC turned THC urine screens positive in nearly every participant, and anyone facing workplace, sporting or custody drug testing should read that as the study's main finding.
Dose-ranging · placebo-controlled · in people · safety, not efficacyNot graded in our registry
2024
Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants
What was actually tested: The pharmacokinetic arm of the same programme (NCT05210634). Twenty-one participants, over six sessions, took placebo and 12.5, 25, 50, 100 and 200 mg of Δ8-THCV in an oral medium-chain-triglyceride formulation. Plasma from 15 of them was collected for up to 8 hours and analysed by validated two-dimensional liquid chromatography–tandem mass spectrometry.
The main metabolite was 11-nor-9-carboxy-Δ8-THCV. The parent compound reached peak concentration after a median of roughly four to five hours, the metabolite a little later, and exposure rose about in proportion to dose. Then the surprise, and the part a QA manager should read twice: Δ9-THCV and its carboxy metabolite turned up in plasma, although a third-party laboratory had found neither in the formulated product. The authors say the possible conversion to the Δ9 isomer “should be further studied”, and the evidence goes no further.
What it shows: The first published human pharmacokinetics for Δ8-THCV: it is absorbed by mouth, peaks after several hours, and rises roughly in proportion to dose.
What it does NOT show: That the Δ8 and Δ9 isomers are interchangeable, or that Δ8-THCV converts to Δ9-THCV in the body. An isomer present in plasma but absent from the product has more than one possible explanation, and the authors ask for further study rather than drawing a conclusion. How often Δ9-THCV appeared, and at what concentration, sits in the full text, beyond the published abstract we report from. Effects are outside it too: a concentration curve measures exposure, and outcomes are a separate question.
Caveat: Mind the isomer, again. Nearly all of THCV's metabolic literature, including the mouse work, the human pilot and the unpublished Phase 2, is about Δ9-THCV; this safety and pharmacokinetic programme used Δ8-THCV. Different molecules, different published pharmacology, one shared abbreviation, and evidence on one does not apply to the other.
Pharmacokinetics · in people · n = 21 enrolled, plasma from 15Not graded in our registry
2026
Metabolite patterns in human urine after oral administration of highly purified Δ8-THCV
What was actually tested: Urine from the same registered programme (NCT05210634), collected before dosing and pooled over 0–8 hours after oral Δ8-THCV. Samples were analysed by a validated online-extraction liquid chromatography–tandem mass spectrometry method and, in parallel, by the kind of routine cannabinoid immunoassay used in toxicology screening.
A cannabinoid immunoassay targeting Δ9-THC-COOH called 70 of 80 pooled post-dose urine samples positive. The reference method, run on the same urine, found mainly the Δ8-THCV carboxy metabolite and no Δ9-THC-COOH at all. The authors conclude that THCV's major urinary metabolites cross-react with immunoassays in routine toxicology use, “resulting in false positive results for Δ9-THC exposure”.
What it shows: In people, a purified THCV product can make a routine urine drug screen read positive for THC when no THC metabolite is present. The false positives are documented, and a confirmatory method proved them false.
What it does NOT show: That THCV is THC, or that anyone was exposed to THC; the reference analysis found none. One assay was tested, in one programme, on Δ8-THCV, so it does not tell you how every immunoassay on the market behaves. The problem itself is real, and now measured.
Caveat: Think about who pays. The practical risk is serious: a positive workplace, sporting or custody drug screen has consequences that land well before anyone runs a confirmatory test, and here a legal product produced a positive result for an illegal one.
Analytical · human urine · documented immunoassay false positivesNot graded in our registry
It can make you fail a drug test for THC
The most consequential practical finding on this page. In a registered human study, 78 of 79 urine screens taken 8 hours after oral THCV were positive for THC (Peters 2023, PMID 37721990). A follow-up analysis found a routine immunoassay flagged 70 of 80 pooled samples as positive, while the reference method found no Δ9-THC metabolite in them (Sempio 2026, PMID 42250012). If you face workplace, sporting or custody drug testing, treat any THCV product as a drug-test risk, whatever its label says about THC content.
“Non-psychoactive” does not survive the higher doses
The marketing says non-psychoactive. The people in the dose-ranging safety study reported euphoric mood as their commonest adverse event, and at 100 mg and 200 mg their ratings of “feel a drug effect” and “like the drug effect” went up. The authors report THC-like effects at higher THCV doses, though mild and not linked to impairment (Peters 2023, PMID 37721990). The receptor data point the same way, since at higher doses the CB1 direction reverses.
Two different molecules share the abbreviation
Nearly all of THCV's metabolic literature concerns Δ9-THCV, while the recent safety and pharmacokinetic programme used Δ8-THCV (Peters 2023; Sempio 2024, PMID 39770444). Separate isomers, separate published pharmacology, and a result for one stays with that one. A jar labelled plain “THCV” leaves you guessing which is inside.
Human exposure is short, and long-term safety is uncharacterised
The longest published human exposure is thirteen weeks, in 62 people, at 5 mg twice daily (Jadoon 2016, PMID 27573936), and the dose-ranging safety work used single acute doses (Peters 2023). A year on THCV, or a drug-interaction study in people, lies beyond anything yet published. The trial that could have widened the picture, the 207-patient, twelve-week Phase 2, recorded adverse events, hypoglycaemia, depression and suicidality scores, and has reported none of them.
Cannabis varieties are not a reliable THCV dose
After a controlled dose of edible cannabis, THCV was never detected in participants' blood at the study's analytical cut-offs (Newmeyer 2017, PMID 28188235). Whatever THCV the plant material contained, eating it left the bloodstream without a measurable amount. A “high-THCV strain” is not a way to get a THCV dose.
The class this compound sits beside was withdrawn for psychiatric harm
CB1 blockers were developed as anti-obesity drugs and dropped after depressive side effects. That history explains why the unpublished Phase 2 registered the Beck Depression Inventory and the Columbia-Suicide Severity Rating Scale as outcomes, and why the human imaging studies take care to call THCV a neutral antagonist rather than an inverse agonist. THCV is a different drug, and nobody has reported such an effect for it. But the psychiatric safety data from its largest trial have never been published, so the question remains open.
Educational, not medical advice
THCV has no approved use in any jurisdiction and is not a treatment for type 2 diabetes, obesity, or any other condition. Nothing here diagnoses, treats, cures or prevents any disease, and nothing here recommends taking THCV or suggests a dose. Nobody should change or stop a prescribed diabetes medicine, metformin included, because of this page. Type 2 diabetes is managed by a clinician, and untreated high blood glucose causes harm a supplement will not prevent. If you take prescription medicines, discuss any cannabinoid product with your prescriber or pharmacist. See safety & reporting and how we grade.
Mechanism
A direction that reverses, and a receptor the literature disagrees about.
Which leaves the question of how THCV works, and the answers come from a different kind of study. A receptor direction is measured at the bench and in animals; a clinical outcome is measured in people. Blend the two and a laboratory result turns into a health claim. Switch to Researcher depth for the cited detail.
In plain terms: THCV works on the same receptors as THC, can push them the other way, and can even reverse itself as the amount changes. At lower amounts it gets in the way of cannabinoids that would otherwise switch the receptor on. At larger amounts, in animals, it starts switching the receptor on instead. At a second receptor, two respected papers from the same research lineage report opposite effects. Both still stand, and we leave the tie unbroken.
Read this first: a correction to our own record, and its source
The 2008 review alone, of all the papers cited for THCV, has a graded record in our registry, and that record summarises its THC and CBD conclusions while leaving THCV out. Yet the paper's title names Δ9-tetrahydrocannabivarin, and its abstract gives four THCV-specific directions. We copied those directions from the abstract, marked them “in the registry — but graded for a different finding”, and kept them off our evidence ladder. An earlier version said the source gave no THCV direction. It was wrong, and the directions now appear in full above.
What our registry record says
Our registry record summarises, in its main finding, the THC and CBD conclusions of a three-compound paper. THCV makes the title and misses the field.
What the paper says about THCV, quoted with its dose condition
“THCV is a CB1 antagonist” is the true half of a sentence whose other half reverses it. So every direction travels with the dose condition under which it holds, in a column of its own where the eye can't skip it.
| Target & preparation | Direction, with the source's own words | Dose condition |
|---|---|---|
| CB2 receptorsIn vitro: cells expressing the receptor. Cells only. | Partial agonist. THCV activates the receptor, though less fully than a full agonist would.“Delta9-THCV behaves as a potent CB2 receptor partial agonist in vitro.”Pertwee 2008, PMID 17828291 Three years earlier, the same laboratory lineage reported the opposite. Thomas 2005 (PMID 16205722), whose senior author went on to write the 2008 review, concludes that “THCV behaves as a competitive CB1 and CB2 receptor antagonist”. At the same receptor, one paper has THCV blocking and the other has it partly switching the receptor on. Both papers stand, and both sit here side by side; we do not choose between them. | In vitro only. The result comes from cells, so the source has no dose to give, and no in-vivo dose has reproduced it in a person. The direction itself is disputed, too; see the contested note. |
| CB1 receptors — in tissueIn vitro: CB1-expressing tissues and cells, challenged with cannabinoid agonists. | Antagonist. THCV stops other cannabinoids acting at CB1. How strongly depends on the tissue and on the agonist it is up against.“In contrast, it antagonizes cannabinoid receptor agonists in CB1-expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent.”Pertwee 2008, PMID 17828291 | In vitro, with an agonist present. The source calls the result tissue-dependent and ligand-dependent, so no single figure carries over from one setting to another. |
| CB1 receptors — in a living animalIn vivo: whole, dosed animals rather than isolated tissue. Animals only. | It flips with dose. THCV acts as a CB1 antagonist, and at higher doses as a CB1 agonist, the opposite action at the same receptor.“Delta9-THCV also interacts with CB1 receptors when administered in vivo, behaving either as a CB1 antagonist or, at higher doses, as a CB1 receptor agonist.”Pertwee 2008, PMID 17828291 | The dose is the finding. The source says “at higher doses”, and nowhere “at low dose”, so we keep to its wording. Antagonism sits below the flip; where the flip sits, the source leaves open, and no human dose has been worked out. The nearest measured figures come from mice dosed intravenously (Pertwee 2007, below). |
| CB1 receptors — where the dose flip was measuredIn vivo: mice given synthetic Δ9-THCV (O-4394) and Δ8-THCV (O-4395) intravenously. | At lower doses both compounds blocked Δ9-THC's effects. At higher doses, given alone, they produced the same agonist-like effects they had been blocking.“By themselves, O-4395 and O-4394 induced ring immobility at 3 or 10 mg kg(-1) (i.v.) and antinociception at doses above 10 mg kg(-1) (i.v.).”Pertwee 2007, PMID 17245367 | Intravenous doses of synthetic compound, in mice: ring immobility appeared at 3 or 10 mg/kg, antinociception at doses above 10 mg/kg. They are the measurement behind “at higher doses”, which is why we print them. They belong to the mouse, and to no oral dose for a person; read them as pharmacology, never as dosing guidance. |
NoteThe shorthand we avoid: “a CB1 antagonist at low dose”
The phrase is the obvious way to sum up the reversal, and it rests on an inference rather than a citation. The source says “at higher doses” and leaves it there: at low dose appears nowhere in it, and it names no threshold. A threshold has been measured in one place, in mice given THCV intravenously (Pertwee 2007), and antagonism is what showed up below the flip. Call that “low dose” in copy someone reads beside a product bottle and you have pinned a human dose band on a mouse experiment. The source's own sentence is the defensible one, and it is the one we use.
The registry anchor, and the paper that contradicts it at CB2
At CB2 the literature splits. Two verified papers report opposite CB2 directions: a partial agonist in one, an antagonist in the other. The senior author of the earlier paper wrote the later review alone, so the split runs through a single research lineage, with different preparations giving different results, which is ordinary pharmacology. CBG Atlas leaves it unresolved. Picking the newer paper, or the one in the bigger journal, would be an editorial call dressed up as a scientific one.
2008
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
What was actually tested: A single-author review of how three phytocannabinoids, Δ9-THC, CBD and Δ9-THCV, act at cannabinoid CB1 and CB2 receptors. It synthesises other researchers' experiments in cells, tissues and animals, and stops short of human data or clinical outcomes.
The review makes four statements about THCV: “Delta9-THCV behaves as a potent CB2 receptor partial agonist in vitro.” · “In contrast, it antagonizes cannabinoid receptor agonists in CB1-expressing tissues.” · “This it does with relatively high potency and in a manner that is both tissue and ligand dependent.” · “Delta9-THCV also interacts with CB1 receptors when administered in vivo, behaving either as a CB1 antagonist or, at higher doses, as a CB1 receptor agonist.” The last carries the mechanism: at CB1, dose decides the direction. Mind the wording, too. The review says “at higher doses”, and nowhere “at low dose”.
What it shows: THCV's cannabinoid-receptor pharmacology has been characterised. It blocks CB1 agonists in CB1-expressing tissues, and in live animals its CB1 action reverses with dose.
What it does NOT show: Any effect, dose or clinical outcome in a person. Receptor pharmacology describes what a compound can do at a receptor; what it does in someone's body is a separate question. Another verified paper (Thomas 2005) contradicts its CB2 statement, which is why that point is marked contested.
Registry status: In the CBG Atlas registry, yes, but the registry summary records only the THC and CBD conclusions of a three-compound paper whose title names Δ9-tetrahydrocannabivarin. The record also supports no graded claim, so it carries a method label (“Review”) in place of a rung on our evidence ladder, and everything above about THCV comes straight from the paper's abstract, ungraded. The omission has been reported for correction. Until it is fixed, we follow the paper over the registry summary.
Review · secondary source · CB1/CB2 pharmacology of three cannabinoidsIn the registry — but graded for a different finding
2005
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
What was actually tested: Radioligand displacement in mouse brain membranes and in cells expressing the human CB2 receptor; functional assays of agonist-stimulated signalling in the same membranes; and antagonism of several cannabinoid agonists in isolated mouse vas deferens. Isolated tissues and cells only.
The paper concludes: “THCV behaves as a competitive CB1 and CB2 receptor antagonist.” The blockade came with conditions. In the vas deferens THCV blocked several cannabinoids more potently than it blocked THC, and it was more potent against two agonists there than in brain membranes. The authors write that “the bases of these agonist- and tissue-dependent effects remain to be established.” At high concentrations THCV also dampened contractile responses by a mechanism unrelated to CB1.
What it shows: In isolated tissues and membranes, THCV competitively blocks cannabinoid agonists at CB1 and CB2, with a strength that depends on the tissue and the agonist.
What it does NOT show: Anything in a person, or a settled CB2 direction: the 2008 review reports a partial agonist at CB2 where this paper found an antagonist. Both findings stand in the literature. The abstract's binding constants are left out.
Caveat: Same lineage, opposite answer. Roger Pertwee is senior author here and sole author of the 2008 review that contradicts it, so the disagreement runs between preparations and years inside one laboratory lineage rather than between rival groups, and that makes it more informative.
In vitro · mouse brain membranes, CHO cells, isolated vas deferens · not peopleNot graded in our registry
2007
The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo
What was actually tested: Synthetic Δ9-THCV (O-4394) and Δ8-THCV (O-4395) were compared with THCV extracted from cannabis, first in binding and functional assays on mouse brain membranes and isolated vas deferens, then in live mice dosed intravenously and challenged with 3 or 10 mg/kg of Δ9-THC.
At intravenous doses of 0.1 to 3 mg/kg, both synthetic compounds blunted THC-induced antinociception and hypothermia in mice. The Δ8 compound also blunted THC-induced ring immobility; the Δ9 compound did not. Then the paper measures what “at higher doses” means: “By themselves, O-4395 and O-4394 induced ring immobility at 3 or 10 mg kg⁻¹ (i.v.) and antinociception at doses above 10 mg kg⁻¹ (i.v.).” Push the dose up and the compounds produced, on their own, the agonist-like effects they had blocked lower down.
What it shows: In mice, THCV blocks THC's effects at lower intravenous doses and produces agonist-like effects of its own at higher ones. The dose-dependent reversal was measured directly.
What it does NOT show: Any human dose. The figures come from synthetic compound injected intravenously into mice and convert to no milligram dose of an oral product, so read them as pharmacology rather than guidance. Metabolism, appetite and weight lay outside the study. The abstract's binding constants are left out.
Preclinical · mice, intravenous · the primary source for the dose flipNot graded in our registry
How our registry grades the same record
CB1 receptors · direction reverses with dosestudy type: Review
According to the registry's verified review, Δ9-THCV blocks cannabinoid receptor agonists in CB1-expressing tissues with relatively high potency, and how well it does so depends on the tissue and the agonist. Put it into a live animal and the picture turns on dose: an antagonist at CB1, and at higher doses an agonist. Where that switch happens, the review leaves open, and no one has established it in a person. All of it is preclinical pharmacology, and it says nothing about any dose a person takes.
Pertwee et al. (2008) · British Journal of PharmacologyPMID 17828291
CB2 receptors · two published directions, in conflictstudy type: Review
At CB2 the record argues with itself. The registry's verified review describes Δ9-THCV as a potent CB2 partial agonist in vitro; an earlier paper from the same laboratory lineage found a competitive antagonist at both CB1 and CB2 (Thomas 2005, PMID 16205722). Both remain in print, neither has been withdrawn, and we take no position on which is right.
Pertwee et al. (2008) · British Journal of PharmacologyPMID 17828291
NoteWhy THCV gets no potency figure here
Ask the papers above for THCV's potency and they give at least three different binding figures, measured in different preparations, against different reference compounds, at different receptors, while two of them disagree about the direction of the CB2 effect. Quote any one of those numbers on its own and it would look precise while amounting to a fabrication. Binding constants stay out of our main text as a rule; THCV is the clearest case for the rule.
Preclinical tracks
Rats and mice, labelled as such.
Away from metabolism, THCV has a second literature, on seizures and Parkinson's disease. All of it is preclinical. It still circulates as though it came from clinics, and one result in particular is routinely reported without the limitation stated in its own abstract.
2010
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
What was actually tested: Three preparations, all from rats: slices of piriform cortex with epileptiform activity induced by magnesium-free media and recorded on a multielectrode array; cannabinoid receptor binding assays in cortical membranes; and pentylenetetrazole-induced seizures in live adult rats.
In the slices, THCV cut the incidence of burst complexes and the amplitude and frequency of paroxysmal depolarising shifts, whether applied to established activity or beforehand. The live-animal result is narrower than summaries make it sound. THCV was tested from 0.025 to 2.5 mg/kg, and only 0.25 mg/kg, one dose in the middle of that hundred-fold range, significantly reduced seizure incidence, with no dose-response relationship reported. In the binding assays THCV bound CB1 without stimulating it, the profile of a neutral antagonist.
What it shows: THCV reduced epileptiform activity in rat brain tissue, and one dose of it reduced chemically induced seizures in live rats.
What it does NOT show: Any effect in a person, or any anticonvulsant claim. One effective dose without a dose-response curve is weaker evidence than a range of doses moving together, and no THCV epilepsy trial in people exists. Epilepsy is a serious condition that needs specialist care, and a rat study treats nobody. The paper's binding constants are left out.
Preclinical · rat brain slices + rats · not peopleNot graded in our registry
2011
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
What was actually tested: Two standard animal models of Parkinson's disease, rats with 6-hydroxydopamine lesions and mice with lipopolysaccharide lesions, given acute or chronic Δ9-THCV. Further experiments used CB2 receptor-deficient mice. Animals throughout.
Acute THCV eased the motor inhibition caused by the 6-hydroxydopamine lesion. Chronic THCV reduced the loss of tyrosine hydroxylase-positive neurones in the substantia nigra, which the authors attribute to its antioxidant properties; a cannabidiol-enriched botanical extract did the same. In the lipopolysaccharide model, where CB2 receptors were more strongly upregulated, THCV also protected those neurones, apparently through CB2.
What it shows: A preclinical signal in two animal models of Parkinson's disease, on both movement and neurone survival.
What it does NOT show: Anything in a person. No THCV trial in Parkinson's disease exists, THCV is no treatment for it, and an animal model is no reason to change Parkinson's medication. A CBD extract reproduced part of the neuroprotective effect, so that part belongs to more than THCV.
Preclinical · rats and mice · not peopleNot graded in our registry
2020
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
What was actually tested: Pitx3-mutant mice, a genetic model of dopamine deficiency, received Δ9-THCV by intraperitoneal injection at 2 mg/kg for two weeks while repeated L-DOPA induced dyskinesia. The researchers measured abnormal involuntary movements and activity, plus FosB protein and a histone marker in the basal ganglia.
Started with the first L-DOPA injection, THCV delayed the onset of dyskinetic signs and made them less severe, and both molecular markers fell to match. Given for three days once dyskinesia had set in, it also eased the signs. The paper restates the dose-dependence of THCV's CB1 action in animals, placing its CB1 antagonist profile at doses lower than 5 mg/kg, a figure for injected doses in animals that translates to no human dose.
What it shows: In a mouse model, THCV delayed and reduced the involuntary movements caused by L-DOPA.
What it does NOT show: Anything about people with Parkinson's disease or L-DOPA-induced dyskinesia; the authors say further studies are needed to establish clinical significance in humans. No THCV trial in Parkinson's disease has been run, and THCV is no treatment.
Caveat: Attribution: the first author is Espadas, though the paper is sometimes credited to García. Concepción García is fifth of seven authors. Get the first author wrong and the citation is broken, however right the DOI.
Preclinical · genetically modified mice · not peopleNot graded in our registry
NoteOne effective dose is not a dose-response
The rat seizure study tested THCV across a hundred-fold dose range, and one point in the middle of that range moved the outcome, with no dose-response relationship reported (Hill 2010). A lone effective dose in the middle of the range is weaker evidence than a series of doses moving the outcome together, and a headline that drops that shape tells half the story. For epilepsy and for Parkinson's disease alike, there is no THCV trial in people, and nothing here amounts to a treatment for either.
Claims refused
What we do not attribute to THCV.
Some THCV claims have a way of coming back. Six of them circulate as evidence, and we turn each one away with the reason and the source attached, so the next time one turns up on a sell sheet the rebuttal is already written.
“THCV is diet weed / an appetite suppressant”
No human result supports it, and the record is unusually clear. The one metabolic trial in patients registered appetite as a secondary endpoint and scored it daily on a 0–10 scale for thirteen weeks (NCT01217112), then published no appetite result. Two imaging studies measured subjective ratings directly, and both were null (Tudge 2015, PMID 25542687; Rzepa 2016, PMID 26362774). And the mouse study the claim is traced to found that THCV “did not significantly affect food intake or body weight gain in any of the studies” (Wargent 2013, PMID 23712280). Everywhere anyone has looked for the effect, it has failed to appear.
“THCV is a proven diabetes treatment”
False. No THCV medicine is approved anywhere, for any indication. The human evidence is a 62-person pilot that missed its registered primary endpoint (HDL), came back null in every combination arm, and drew its glucose result from about a dozen people taking THCV for thirteen weeks (Jadoon 2016, PMID 27573936). The trial designed to test the idea properly, with 207 patients and HbA1c as primary, completed in 2016 and was never published (NCT02053272). A blood-marker shift in a pilot does not make a treatment, and the trial meant to test it is still private.
“THCV is non-psychoactive”
Not as a blanket statement. In a registered human study, 100 mg and 200 mg of THCV raised ratings of “feel a drug effect” and “like the drug effect”, the authors report THC-like effects at higher THCV doses, and the commonest adverse event was euphoric mood (Peters 2023, PMID 37721990). The receptor pharmacology agrees, since the CB1 direction reverses at higher doses. “Non-intoxicating at the doses in a typical product” might be defensible. “Non-psychoactive” without qualification goes past the evidence.
A single THCV binding figure
The papers cited on this page report at least three different binding constants, measured in different preparations, against different radioligands, at different receptors, and two of them disagree on the direction of the CB2 effect. Pull any one number from that set and it would look precise while misleading the reader, so we print none; binding constants stay out of the main text across the site.
“A high-THCV strain will give you a THCV dose”
Not supported. After a controlled dose of edible cannabis, THCV was never detected in participants' blood at the study's analytical cut-offs (Newmeyer 2017, PMID 28188235). Whatever the certificate of analysis says about the plant material, eating it put no measurable THCV into the bloodstream. The human studies that did find THCV in plasma all used a purified compound at a known milligram dose.
Δ8-THCV evidence is not Δ9-THCV evidence
The metabolic literature, meaning the mouse studies, the human pilot and the unpublished Phase 2, is about Δ9-THCV; the recent safety, pharmacokinetic and drug-screen work is about Δ8-THCV. Two isomers, distinct published pharmacology, one shared abbreviation. We name the isomer wherever a study used one and keep each finding with the molecule it was measured on.
THC vs THCV vs CBDV vs CBN
Four columns, because two would hide the point.
Put THCV beside its pentyl counterpart, its propyl sibling, and CBN, the platform's other pillar built on a missed primary endpoint, and the family resemblance turns out to be skin deep. THC, CBDV and CBN are there as reference chemistry, and each column's evidence stays in its own column.
| Property | THC (pentyl · reference) | THCV (the subject · propyl) | CBDV (propyl) | CBN (oxidation product) |
|---|---|---|---|---|
| Side chain | Pentyl, five carbons. C₂₁H₃₀O₂ · 314.5 g/mol. | Propyl, three carbons. C₁₉H₂₆O₂ · ≈ 286.4 g/mol. Two carbons shorter than THC. | Propyl, three carbons. C₁₉H₂₆O₂ · ≈ 286.4 g/mol. Same formula as THCV on a different skeleton. | Pentyl, on an oxidised ring. C₂₁H₂₆O₂ · ≈ 310.43 g/mol. |
| Where it comes from | CBGA → THCA synthase → THCA → heat removes CO₂ → Δ9-THC. | CBGVA → THCA synthase → THCVA → heat removes CO₂ → Δ9-THCV. A parallel line with its own acid, step for step, rather than a shortened THC. | CBGVA → CBDA synthase → CBDVA → heat removes CO₂ → CBDV. Same varin precursor, different synthase. | A breakdown product rather than a plant end product: CBN forms as Δ9-THC and THCA oxidise with air, light and time. |
| Cannabinoid-receptor direction | CB1 and CB2 partial agonist, which is the basis of intoxication. Shown for reference; THC has no pillar page of its own. | Depends on dose. Blocks CB1 agonists in CB1-expressing tissues. In live animals, a CB1 antagonist, or a CB1 agonist at higher doses. At CB2 the papers conflict: partial agonist in one, antagonist in another. | Not stated here. The CBDV pillar covers what its own record shows. | Not stated here. After a CBN dose, most of the cannabinoid-receptor activity comes from a metabolite rather than CBN itself; see the CBN pillar. |
| What it was tested FOR in people | Not covered as a pillar here. | Metabolic outcomes in type 2 diabetes; blunting THC's effects; safety and pharmacokinetics of single doses. | Seizures, HIV-associated neuropathic pain, and autism-related brain imaging. | Sleep, and little else. Every modern CBN trial in people has been a sleep trial. |
| How the trials went | — | The metabolic pilot missed its primary endpoint (HDL was unaffected) and every combination arm was null. The 207-patient phase 2 with HbA1c as primary was never published. | Four published, including a Phase 2 randomised controlled trial in focal epilepsy. None met a primary efficacy endpoint. | Three tested CBN for sleep. The two with a pre-specified primary endpoint both missed it, and the third names no registration. |
| The claim it is sold on | — | “Diet weed”: appetite suppression and weight loss. No positive human appetite result exists, and the trial that registered appetite as a secondary endpoint never reported it. | That its close name and scaffold give it CBD's clinical standing. | “The sleep cannabinoid”, which treats a secondary or tertiary positive as if it were a primary endpoint. |
| The caution that travels with it | Intoxication and its consequences. | Drug tests. A legal THCV product turned THC urine screens positive in nearly every participant, with documented immunoassay false positives. And “non-psychoactive” fails at the higher tested doses. | Liver enzymes. Transaminase elevations appeared in two independent CBDV studies. | Melatonin. In mice, CBN inhibited the enzyme that clears melatonin and raised melatonin exposure four-fold, and the two are sold together in the same capsule. |
| Approved medicine | — | None, for any indication, in any jurisdiction. | None, in any jurisdiction. | None, in any jurisdiction. |
| Does the neighbouring column transfer? | NO. | NO, and this is where people most often assume it does. Far from “THC lite”, THCV is a different molecule made from a different acid, and depending on dose its receptor action can run opposite to THC's. | NO. Sharing a formula with THCV says something about atoms and nothing about evidence. | NO. Being a cannabinoid is a structural fact, and evidence stays with the molecule it was gathered on. |
NoteSharing a formula is not sharing evidence
THCV and CBDV have the same molecular formula and come from the same precursor, and their evidence could hardly look less alike. CBDV has been through a Phase 2 trial in focal epilepsy; THCV, through a metabolic pilot in 62 people. The kinship with THC runs just as thin: two carbons apart, and able to pull in opposite directions at the same receptor. Each of the four stands on its own studies. On a label or a spec sheet, evidence for one varin tells you nothing about the other.
Research roadmap
What new evidence would change what we say about THCV?
The first item on the list is the cheapest by far. It asks for science that already exists to be released, which costs a fraction of running another trial.
01
Publish the trial that already exists
The most valuable addition to THCV's evidence needs no new volunteers and no new money, because the trial has already been run. 207 people completed a twelve-week Phase 2 with HbA1c as its primary endpoint in February 2016, and no results or paper have appeared since (NCT02053272). Publishing it would answer the metabolic question one way or the other, and it would put twelve weeks of unreported safety, hypoglycaemia, depression and suicidality data on 207 people into the record. Until then, every metabolic summary of THCV, ours included, is working from part of the evidence.
02
An appetite endpoint that is actually reported
Appetite is what THCV is sold on, and no human study has produced a positive result for it. One trial registered it as a secondary endpoint and scored it daily for thirteen weeks, then left the outcome unpublished; two others measured subjective ratings and found them flat. What would move our assessment is a trial with appetite or food intake as a pre-specified primary endpoint, reported whatever the result. A null would be as useful as a positive, and considerably more likely.
03
Settle the CB2 direction, and find the dose flip in a person
Two verified papers from the same research lineage give opposite CB2 directions, and both remain unretracted; a modern head-to-head characterisation in one preparation would settle it. Separately, the switch from antagonist to agonist has been located only in mice given THCV intravenously, and for a person taking THCV by mouth the threshold is unknown, though it marks the line between a dose that blocks cannabinoid signalling and one that mimics it.
04
Human data on the isomer that is actually being sold
Products just say “THCV”, while the metabolic evidence concerns Δ9-THCV and the recent safety, pharmacokinetic and drug-screen work concerns Δ8-THCV. Isomer-labelled human pharmacokinetics and repeat-dose safety data for both would tell a buyer which body of research applies to the jar in hand, and show whether the Δ9-THCV found in plasma after a Δ8-THCV dose comes from conversion in the body, a question the authors who saw it have flagged for further study.
References & further reading
Where every THCV claim here comes from
The papers behind the argument, grouped by standing: a graded record from our evidence registry, then the rest, published, checkable and ungraded here, and finally a trial registration with no published result.
In our evidence registry: graded, and cited for a finding its registry summary omits
2008
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
Review · secondary source · CB1/CB2 pharmacology of three cannabinoids
THCV papers cited here, ungraded in our registry
Show all 15 papers, with PubMed and DOI
2016
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Randomised, placebo-controlled · in people · pilot · primary endpoint missed
2016
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
Crossover pilot · in people · n = 10 · an interaction study, not an efficacy trial
2015
Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers
Randomised crossover · in people · n = 20 · brain imaging, not eating
2016
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
Randomised crossover · in people · n = 20 · resting-state imaging
2013
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity
Preclinical · mice · four dose-ranging studies · not people
2017
Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration
Controlled human dosing · analytical chemistry · not a THCV trial
2025
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management
Narrative review · single author · secondary source · asserts more than the primaries show
2023
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants
Dose-ranging · placebo-controlled · in people · safety, not efficacy
2024
Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants
Pharmacokinetics · in people · n = 21 enrolled, plasma from 15
2026
Metabolite patterns in human urine after oral administration of highly purified Δ8-THCV
Analytical · human urine · documented immunoassay false positives
2005
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
In vitro · mouse brain membranes, CHO cells, isolated vas deferens · not people
2007
The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo
Preclinical · mice, intravenous · the primary source for the dose flip
2010
Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats
Preclinical · rat brain slices + rats · not people
2011
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
Preclinical · rats and mice · not people
2020
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Preclinical · genetically modified mice · not people
A registration, with no result in the public record
NCT02053272: “A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes”. Phase 2: randomised, double-blind, placebo-controlled, parallel-group, dose-ranging. Completed. Started February 2014; primary completion February 2016; overall completion February 2016. None. No paper on this trial has appeared; a PubMed search for the compound code “GWP42004” returns zero records (checked 2026-08-23). It earns its place here precisely because other THCV reference lists leave it out: they are built from publications, and this trial produced none. ClinicalTrials.gov →
For the compound with our deepest graded record, read the CBG monograph. THCV's varin relatives, CBGV and CBDV, have their own pages, and the other pillar built on a set of missed primary endpoints is CBN. For how a claim earns a rung, see how we grade.
Identity & origin
Show the answers 4
What is THCV (tetrahydrocannabivarin)?
THCV is a minor cannabinoid that cannabis and hemp make naturally, the propyl relative of THC, with a shorter side chain, and it acts differently at the CB₁ receptor. In lab tissue it antagonises cannabinoid agonists acting through CB₁; in living animals it behaves as a CB₁ antagonist or, at higher doses, as a CB₁ agonist (Pertwee 2008, PMID 17828291).
What does "tetrahydrocannabivarin" mean?
The name is a chemistry lesson in one word. "Cannabi" marks a cannabinoid, and "varin" places it in the varin series, which carries a three-carbon (propyl) side chain where THC has a five-carbon (pentyl) one. That shorter chain is all that separates THCV from THC, which makes it THC's varin homolog.
Where does THCV come from?
From the plant's varin (propyl) branch. There the parent acid CBGVA becomes THCVA, which sheds its acid group under heat and turns into THCV. Most plants carry only small amounts; certain varieties carry noticeably more.
Is THCV natural or synthetic?
Natural: the plant makes it directly. Commercial THCV may be extracted and purified from cannabis or hemp, or produced in a lab, and both routes arrive at the same molecule.
Psychoactivity
Show the answers 4
Does THCV get you high?
It may, depending on the dose, which makes a flat "non-intoxicating" label on a THCV product hard to defend. In lab tissue THCV antagonises cannabinoid agonists acting through CB₁. In living animals it acts as a CB₁ antagonist or, at higher doses, as a CB₁ agonist, the receptor THC works through (Pertwee 2008, PMID 17828291). Where that switch happens in a person is still unknown.
Is THCV psychoactive?
It depends on the dose, and the question hides a distinction: "psychoactive" is a wider word than "intoxicating". THC switches the CB₁ receptor on. THCV antagonises cannabinoid agonists there instead, though in animals it turns to CB₁ agonism at higher doses (Pertwee 2008, PMID 17828291). What it does to mood or perception in people remains poorly characterised.
What does THCV feel like — is it energizing or clear-headed?
Controlled human studies have not established what THCV feels like. THCV is sold as "energizing" and "clear-headed", and some users describe it that way, but those are anecdotes, and the experience shifts with the person, the dose and the product. Read those adjectives on a label as marketing copy. (Not medical advice.)
Is THCV a stimulant?
No. THCV carries no stimulant classification and has no verified stimulant pharmacology. Its established lab activity sits at cannabinoid and TRP receptors, well away from the pathways stimulant drugs work on, and the "energy" effect some sellers promote has not been established. (Not medical advice.)
Legality
Show the answers 4
Is THCV legal?
It depends on where you are and when you ask. As of 2026, US federal status rests on the 2018 Farm Bill and on "total-THC" rules that are still moving, state laws differ, and other countries apply their own frameworks. A product that is lawful today could be off the shelf tomorrow. General information, not legal advice; check the rules where you are.
Is THCV legal federally (2018 Farm Bill)?
Probably, though the uncertainty is real. The 2018 Farm Bill legalized hemp and hemp derivatives containing under 0.3% delta-9 THC by dry weight, and many read that to cover hemp-derived THCV. Shifting "total-THC" interpretations and pending rules could still change the answer. Status as of 2026; general information, not legal advice.
Is THCV legal in every US state / mine?
No. Some states restrict or ban hemp-derived cannabinoids such as THCV even where federal rules allow them, and the map moves often enough that your own state's current law is the only reliable guide. Check it, or ask a qualified attorney. As of 2026; general information, not legal advice.
Is THCV legal in the UK, EU, or Canada?
Each runs its own cannabis and novel-food law, and the US Farm Bill stops at the border. Canada regulates THCV under the Cannabis Act. The UK and EU handle cannabinoids through controlled-substance and novel-food frameworks, and neither has specifically authorised THCV. Status varies and changes; general information, not legal advice.
Effects & benefits
Show the answers 5
What are the benefits of THCV?
No human benefit of THCV has been established. What has been verified comes from the lab and from animals: dose-dependent behaviour at the CB₁ receptor and effects on TRP channels (Pertwee 2008; De Petrocellis 2011). The benefits on the label, appetite control and energy above all, have not been shown in controlled human studies, and our registry holds no primary evidence for any of them. (Not medical advice.)
What is THCV used for?
Mostly for selling wellness and hemp products, on promises of appetite management, energy or metabolic "support". Those are marketing claims. THCV holds no approved therapeutic indication, and controlled human evidence for these uses is lacking, so a label promising them has no clinical data behind it. (Not medical advice.)
Does THCV help with appetite or weight loss?
No published human result shows that it does. The "diet weed" reputation comes from proponents and from preliminary animal research suggesting THCV may suppress appetite, and no controlled human study has established it. Nothing in our registry shows THCV moving appetite or body weight in a person. THCV is neither an approved nor a proven weight-loss product, and it has no place in anyone's plan for weight management. (Not medical advice.)
Does THCV help with diabetes or blood sugar?
Nothing establishes that it does, and prescribed medication should stay exactly as your doctor set it. Proponents point to early and preclinical research on THCV and metabolic or blood-sugar measures. Most of that work sits outside our registry and has never been established in humans; what we hold includes no case of THCV lowering blood sugar in a person. THCV is not a treatment for diabetes or any metabolic condition. (Not medical advice.)
Was THCV ever tested in a large clinical trial?
Yes, and the results were never published. A 207-participant Phase 2 trial of THCV (NCT02053272) was registered and completed, and its findings have not appeared in the literature. That sets THCV apart from a compound nobody has tested, or one that tested flat: here the trial ran at scale and the answer stopped short of the record. We can't grade an unreported result or infer one from the trial's existence, but anyone citing THCV research should know the trial is out there.
Safety & side effects
Show the answers 4
Is THCV safe?
It's too early to say either way. Long-term human safety data on THCV are limited, and its tolerability and effects across different populations remain poorly mapped. Check with a qualified professional before use, especially if pregnant, nursing or taking medication. (Not medical advice.)
What are the side effects of THCV?
Nobody has a reliable list yet. THCV's side effects in humans remain poorly characterised, controlled data are limited, and reactions to any cannabinoid vary from person to person. Stop use if you feel unwell, and report any adverse effect to a professional. (Not medical advice.)
Can you take too much THCV?
Nobody knows where "too much" begins. No safe dose or toxicity threshold for THCV has been defined in humans, so there is no reliable safe maximum, and we give no dosing guidance. Taking more is not better. Talk to a qualified healthcare professional before using cannabinoid products. (Not medical advice.)
Does THCV interact with medications?
Interaction data specific to THCV are limited. Cannabinoids as a class can change how the body processes some medications, so anyone on prescription drugs, including blood-pressure or other cardiovascular medicines, should talk with a doctor or pharmacist before use. (Not medical advice.)
Drug testing
Show the answers 3
Will THCV show up on a drug test?
Possibly. Standard drug tests look for THC and its metabolites rather than THCV itself, but structurally similar cannabinoids can sometimes cross-react, and many THCV products legally carry trace THC that a test will catch. How THCV behaves on these tests remains poorly characterised, so a pass is something nobody can promise.
Does THCV contain THC?
Pure THCV contains no THC; it is a separate molecule, the propyl homolog of THC. Products made from cannabis or hemp can still carry trace THC and other cannabinoids alongside it, so the THC figure on the product's lab report is the number to check.
Can THCV make you fail a drug test?
It could. The bigger risk is the trace THC found in many THCV products, since the tests are built to find THC, and cross-reactivity from related cannabinoids adds some uncertainty on top. Anyone subject to drug testing is safest avoiding these products.
Usage & dosing
Show the answers 4
How do you take THCV?
The same ways as other cannabinoids: oils and tinctures held under the tongue, capsules, edibles and gummies, and vapes or flower for inhaling. The route changes how quickly effects start and how long they last. How much to take is a separate question, and we give no dosing advice.
What THCV products are there?
Oils and tinctures, capsules and softgels, gummies and other edibles, vape cartridges, and cannabis flower or concentrates naturally higher in THCV. Purity and actual THCV content swing widely between products, which is why the third-party lab report matters. We don't endorse any brand.
How much THCV should I take?
No THCV dose has been established or clinically validated, and we make no dosing recommendations. Effects appear to depend on dose (in animals the receptor direction reverses at higher doses), yet reliable human dosing data don't exist. Discuss any use with a qualified healthcare professional. (Not medical advice.)
How long does THCV take to work and last?
Mostly as long as the format dictates. Inhaled products generally act within minutes, while oils and edibles take longer because they are absorbed through the mouth or gut. Onset and duration for THCV itself remain poorly characterised in the literature, and people respond differently. We give no dosing guidance.
Comparisons
Show the answers 4
THCV vs THC — why the "diet weed" myth?
Because the two molecules act differently at the same receptor, and marketing turned that contrast into a promise. THCV's side chain has three carbons (propyl); THC's has five (pentyl). THC activates CB₁ and intoxicates, while THCV antagonises CB₁ and only switches to agonism at higher doses (Pertwee 2008). The appetite claim built on that difference has not been established.
THCV vs CBD — what's the difference?
They are different molecules with different pharmacology, though both are non-intoxicating at typical or low doses. CBD comes from CBDA; THCV is the propyl relative of THC, made on the varin branch. In lab studies the two engage different receptor profiles (Pertwee 2008; De Petrocellis 2011), and CBD has far more human research behind it.
THCV vs CBG for energy?
Neither has been shown to provide energy. Both are non-intoxicating minor cannabinoids that act at different receptor targets in the lab, and both are marketed for "energy" and "focus". No controlled human study has established either effect, and nothing we hold ranks one above the other. Product testing is firmer ground for a choice than the marketing. (Not medical advice.)
THCV or THC — which for appetite?
Only THC has the evidence. Its increase in appetite through CB₁ activation is well established, while THCV is marketed for the opposite, appetite suppression, and we hold no primary evidence that it does that in a person. Leave THCV out of any plan to manage appetite. (Not medical advice.)
Chemistry & production
Show the answers 5
What is THCV's formula and structure?
THCV's molecular formula is C₁₉H₂₆O₂ and its molecular weight is about 286.41 g/mol (CAS 31262-37-0; PubChem CID 93147). The structure matches THC except for the side chain, a three-carbon propyl chain in place of THC's five-carbon pentyl chain, and that shorter chain earns it the "varin" name.
How is THCV made or extracted?
In the plant, enzymes on the varin branch turn CBGVA into THCVA, and heat then decarboxylates THCVA (it loses CO₂) to give THCV. Commercial THCV is extracted from cannabis or hemp that contains it and purified by chromatography, or produced in a laboratory.
Is THCV a varin of THC (shorter side chain)?
Yes. THCV is the varin (propyl) homolog of THC, alike in every respect but one: a three-carbon side chain where THC has a five-carbon one. That single change accounts for THCV behaving differently from THC, down to a receptor direction that shifts with dose.
What is THCVA — does THCV come from an acid?
Yes. In the raw plant THCV exists as THCVA (tetrahydrocannabivarinic acid, C₂₀H₂₆O₄; CAS 39986-26-0). Heated to roughly 110–130 °C, THCVA decarboxylates, shedding its carboxyl group as CO₂, and becomes THCV. Raw THCVA is non-intoxicating; THCV appears only once the material meets heat.
Is Δ8-THCV the same as Δ9-THCV?
No. They are different isomers, and the difference matters when reading the research. "THCV" usually means Δ9-THCV. Δ8-THCV has its own pharmacology, and some of the human dose-ranging work often cited for THCV was run on the Δ8 form, so a result for one isomer is not automatically a result for the other. A source that leaves the isomer unnamed passes that ambiguity straight on to its findings.
Buying & trust
Show the answers 5
Where can I buy THCV?
Online from hemp and cannabinoid retailers and, where it is legal, in dispensaries and specialty stores. Availability depends heavily on local law (see the legality answers). Quality swings widely, so buy only from sellers who provide third-party lab testing. We don't endorse specific vendors.
Why is THCV rare or expensive?
Because the plant makes so little of it. Most cannabis contains only small amounts of THCV, so producing it takes specialised higher-THCV cultivars plus extra extraction and purification. Scarce raw material and added processing make THCV scarcer and dearer than mainstream cannabinoids such as CBD.
How do I know a THCV product is real (COA)?
Ask for a current Certificate of Analysis (COA) from an independent third-party lab. It should confirm that the THCV content matches the label, report THC levels, and screen for contaminants such as pesticides, solvents and heavy metals. A missing or vague COA is a red flag.
Is THCV worth trying?
Your call, but weigh the record first. THCV's main selling points (appetite, energy, metabolic benefits) have not been established in humans, we hold no primary evidence for any of them, and safety and dosing data are limited. Anyone considering it should talk with a qualified healthcare professional first. (Not medical advice.)
What should I look for when buying THCV?
Transparency first: a recent third-party COA that verifies THCV content and screens for contaminants, accurate labelling of every cannabinoid amount including any THC, and a seller you can identify and contact. Confirm the product is legal where you live, and be wary of health claims that run ahead of the evidence.
More questions people ask
Show the answers 10
Can you take THCV and CBD together?
Some products already combine them, and some users pair the two expecting complementary effects, but controlled human studies have not established that the pair does more than either compound alone. THCV's effects depend on dose: non-intoxicating at low doses, potentially more THC-like at higher ones. Ask a clinician if you take other medicines. (Not medical advice.)
How long does THCV stay in your system?
Nobody can give a reliable figure. THCV is fat-soluble, like other cannabinoids, and may linger, but human elimination data specific to it are limited, and we won't publish numbers we can't verify. For drug testing, the bigger issue is the trace THC that THCV products may contain.
Can you build a tolerance to THCV?
Unknown; nobody has studied whether repeated THCV use produces tolerance in humans. THCV's effects appear to depend on dose, with low-dose behaviour differing from high-dose behaviour, but a dose curve and a tolerance are different things. If effects change over time, review your use with a clinician rather than steadily taking more. (Not medical advice.)
Is THCV addictive?
No clear evidence says THCV is addictive, but caution is warranted. At low doses it blocks CB₁ and does not intoxicate. At higher doses, lab studies suggest it may activate CB₁ more like THC, whose dependence potential is documented. THCV's own abuse liability has not been formally studied in humans. (Not medical advice.)
Can you take THCV every day, or long-term?
There is no established answer. THCV has no controlled human studies of repeated daily use, higher amounts or long-term safety, and because its profile changes with dose, the amount matters. Anyone considering regular use, particularly alongside other medication, should discuss it with a qualified clinician first. (Not medical advice.)
Does THCV affect blood pressure or heart rate?
That has not been established. THCV's cardiovascular effects in humans have not been well studied, and at higher doses it may show more THC-like CB₁ activity, so caution is reasonable. People with a heart condition or on cardiovascular medication should consult a clinician before using THCV. (Not medical advice.)
Can you drive after taking THCV?
Be careful, because the answer depends on dose. At low doses THCV is described as non-intoxicating, but lab studies suggest that at higher doses it may act more like intoxicating THC, and products can contain trace THC. Impairment remains poorly characterised, so stay off the road if you feel any effect. (Not medical advice.)
Is THCV safe for dogs or pets?
It cannot be called safe for pets. Veterinary data on THCV are very limited, animals can be more sensitive than people, and products may contain trace THC, which is toxic to dogs. Never dose an animal yourself; ask a veterinarian first. (Not medical advice.)
Can you take THCV while pregnant or breastfeeding?
Avoiding it is the safest course. The FDA strongly advises against using CBD, THC or marijuana in any form while pregnant or breastfeeding, and THCV's safety in pregnancy has not been established. Speak with an obstetrician or midwife before using any cannabinoid product. (Not medical advice.) THCV products may also contain trace THC.
Is THCV stronger or more potent than THC?
Neither is simply stronger, because they work differently. THCV, the propyl relative of THC, has a dose-dependent profile: it blocks CB₁ at low doses without intoxicating and may activate it at higher doses, while THC intoxicates reliably. With a difference in kind, "more potent" and "less potent" both misdescribe it, and effects vary by dose and person.
Before you act on what you read about THCV
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event → Compound monographs
The rest of the family.
Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.
Cannabigerol (CBG)
The mother cannabinoid. CBGa decarboxylates to CBG, and both occur in the plant. The three synthases act on CBGa, the acid, branching it into THC, CBD and CBC. CBG carries more evidence than any other compound on the platform.
Cannabigerolic acid (CBGa)
The acid CBG comes from, and the shared substrate the three branch synthases compete for. Heat decarboxylates it to CBG.
Cannabigerovarin (CBGV)
The propyl (varin) analogue of CBG, with a three-carbon side chain in place of five.
Cannabichromene (CBC)
One of the three branches off the shared CBGA substrate, and a non-intoxicating one.
Cannabinol (CBN)
Forms as THC ages and oxidises, so it builds up in stored material rather than being made by the plant directly.
Cannabidivarin (CBDV)
CBD's propyl analogue, and the varin with the largest published human trial record.
Keep exploring
Its acid or neutral form
Head-to-head